Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Diagnosis and management of thalassaemia

M Peters, H Heijboer, F Smiers and P C Giordano
BMJ: British Medical Journal
Vol. 344, No. 7841 (28 January 2012), pp. 40-44
Published by: BMJ
Stable URL: http://www.jstor.org/stable/41503391
Page Count: 5
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Preview not available

Abstract

SUMMARY POINTS The changing demographic features of thalassaemia, with its widely variable phenotypes, have implications for diagnosis, counselling, and management Carriers of thalassaemia require no specific treatment but should be protected from iron supplementation, which may be detrimental Antenatal and neonatal screening for thalassaemia may reduce the number of severely affected children Monitoring iron overload and chelation therapy in transfusion dependent thalassaemia patients is essential to prevent fatal cardiomyopathy and liver cirrhosis The only potential cure for β thalassaemia is hematopoietic stem cell transplantation

Page Thumbnails

  • Thumbnail: Page 
40
    40
  • Thumbnail: Page 
41
    41
  • Thumbnail: Page 
42
    42
  • Thumbnail: Page 
43
    43
  • Thumbnail: Page 
44
    44